



Published in final edited form as:

Curr Breast Cancer Rep. 2013 December ; 5(4): . doi:10.1007/s12609-013-0125-9.

Breast Cancer Biomarkers: Utility in Clinical Practice

Fanny Le Du^{1,2}, Naoto T. Ueno¹, and Ana M. Gonzalez-Angulo^{1,3}

¹Department of Breast Medical Oncology, The University of Texas M.D. Anderson Cancer Center, Houston, TX, USA

²Department of Medical Oncology, Eugène Marquis Cancer Center, Rennes, France

³Department of Systems Biology, The University of Texas M.D. Anderson Cancer Center, Houston, TX, USA

Abstract

Breast cancer is a heterogeneous disease. For the past decades, new technical tools have been developed for biomarkers at the DNA, RNA and protein levels to better understand the biology of breast cancer. This progress is essential to classify the disease into clinically relevant subtypes, which may lead to new therapeutic opportunities. Novel biomarker development is paramount to deliver personalized cancer therapies. Further, tumor evolution, being natural or under treatment pressure, should be monitored and “liquid biopsies” by detecting circulating tumor cells or circulating free tumor DNA in blood samples will become an important option. This paper reviews the new generation of biomarkers and the current evidence to demonstrate their analytical validity, clinical validity and clinical utility.

Keywords

Biomarkers; Breast cancer; Prognosis; Prediction; Clinical utility

Introduction

Breast cancer is the most frequent female neoplasm. For early breast cancer, standard treatment remains complete excision with or without radiotherapy. Indication of an adjuvant systemic treatment is based on standard prognostic characteristics as age, menopausal status, tumor size, lymph node status, histological grade, estrogen receptor (ER) and HER2 status. To help clinicians, *Adjuvant!Online* (AOI), an easy computer-based nomogram, combines some of these markers to evaluate recurrence and death risks with or without adjuvant systemic therapy. However, this clinical tool widely used in practice presents some drawbacks: the prognostic prediction is only based on stage of disease (tumor size, node involvement), tumor grade and ER positivity; treatment effectiveness is adjusted only for age and ER positivity in postmenopausal patients; and the validation was obtained on

Corresponding author: Ana M. Gonzalez-Angulo, MD, Department of Breast Medical Oncology, Unit 1354, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030-4009; Tel: (713) 792-2817; Fax: (713) 794-4385; agonzalez@mdanderson.org.

Compliance with Ethics Guidelines

Conflict of Interest

Fanny Le Du declares that she has no conflict of interest.

Naoto T Ueno has received a grant from Apocell.

Ana M. Gonzalez-Angulo has received a grant from Genomic Health.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

patients without major co-morbidities and <70 years of age [1]. Therefore, patients with same risk and same treatment have different outcomes, an indication of breast cancer heterogeneity. During the last few years, research has focused on identification of potential markers (specified DNA sequence, RNA levels or expressed protein) to improve sub-group classification and correlate it with clinical outcome and therapy response. We will review some of the most promising biomarkers focusing on their reproducibility and robustness (analytical validity), their ability to identify accurately relevant breast cancer survival (clinical validity) and how these biomarkers could favor a better approach of the treatments (clinical utility) [2]. In addition we will also review the role of “liquid biopsies” in detecting circulating tumor cells (CTCs) or circulating free tumor DNA (cfDNA) in blood samples as a biomarker option.

Molecular testing for early breast cancer

Nowadays, many new tools in the field of molecular profiling have been developed for early-breast cancer to accurately predict outcomes and to estimate the benefit of adjuvant treatment. We will first discuss of tumor tissue markers from gene expression assays (summarized in Table 1 [3]) to proteomics assays, and then, we briefly analyze the germline markers.

Tumor tissue markers

Gene expression assays—OncotypeDX® measures 21 genes by quantitative reverse transcriptase-PCR (qRT-PCR), using formalin-fixed paraffin-embedded (FFPE) tissues to determine a Recurrence Score (RS). This score estimates the likelihood of distant metastasis at 10 years from the date of diagnosis, and stratifies patients in to three risk groups: low, intermediate and high for RS values <18, 18–30, >30, respectively [4]. Scientific societies such as ASCO® [5], NCCN® [6] and ESMO [7] have recently included the OncotypeDX assay in their guidelines. The analytical value of this biomarker was assessed by a high reproducibility (Pearson’s $r=0.86$) [8]. It was firstly validated as an independent prognosis marker [4] then as predictive of tamoxifen response[9] for ER-positive, lymph-node negative early stage breast cancer in the NSABP-B14 population. In NSABP-B20 cohort of ER-positive, node-negative patients tamoxifen-treated with or without chemotherapy, RS assay was assessed as predictor of chemotherapy response [10]. In the most recent TransATAC study, RS prognostic value was highlighted in post-menopausal both node negative and positive patients, treated either by tamoxifen or anastrozole [11]. The prognostic value and predictive response to chemotherapy was also validated in the node positive SWOG8814 cohort. No benefit of CAF-regimen chemotherapy was proved for low-RS ($p=0.97$) but an increased disease-free survival (DFS) was highlighted for high-RS group ($p=0.03$) [12]. Others studies revealed that the 21-gene signature was better than standard clinicopathological variables at predicting recurrence [13]. But even with these new classifiers, results remain intermediate for 22 % to 40% of the population for whom prognosis are still heterogeneous and treatment decisions still difficult [4,14]. Studies have shown that in approximately 30% of cases, knowledge of RS results impacts the oncologist’s recommendation. Most changes were from combined chemo-endocrine therapy to endocrine therapy alone [15,16], but impact on outcomes was not studied. Phase III trials are ongoing to prospectively validate clinical utility. The TAILORx and the RXPONDER trials will validate the clinical utility of Oncotype DX® to assign ER-positive to adjuvant systemic treatment. They both investigate whether hormone therapy alone or hormone therapy together with combination chemotherapy is better for women who have an RS of 11–25, in node-negative for TAILORx and node-positive cohort for RXPONDER [17,18].

MammaPrint® evaluates the expression level of 70 genes on fresh-frozen or FFPE tissue sample to define low or high risk of relapse. This DNA-microarray has been FDA approved

as a prognosis marker of distant metastasis free survival for T1-2 early breast cancer [19–21], after a 100% inter-laboratory concordance was obtained (failure rate of 19% because of insufficient samples) [21]. Similar to the 21-gene RS, the 70-gene signature outperforms the clinicopathological risk indexes habitually used (e.g. AOI) with a discordance rate of 37% and a larger low risk population [21–23]. On ER-positive population, *Knauer et al.* [24] studied in a pooled analysis the benefit of adding chemotherapy to endocrine treatment among high risk patients compared to low risk patients. However, the test for interaction was not significant and the predictive value of the signature was not validated. *Straver et al.* [25] showed that a pathological complete response (pCR) after neoadjuvant chemotherapy was unlikely in the good prognosis-signature group versus the poor one. The MINDACT European project prospectively will validate the clinical utility of Mammaprint® as a predictor of chemotherapy benefit [26,27].

The **PAM50 assay**, a qRT-PCR of 50 genes, identifies five “intrinsic” subgroups of breast cancers: luminal A, luminal B, HER2-enriched, normal-like and basal-like [28]. This assay provides a risk of relapse (ROR) score, predicting the likelihood of recurrence over 10 years. These subtypes combined with usual clinical variables improve prediction of relapse at 5 years for node negative or positive breast cancer [29]. PAM50 results are concordant with Oncotype DX®: 83% of the low RS are luminal A [14]. Moreover, ROR is predictive of pCR after neoadjuvant chemotherapy with a sensitivity of 97% and a negative predictive value (NPV) of 97% [29] with a pCR rate for luminal A and HER2-enriched of respectively 3% and 50% [30]. The utility of PAM50 could be into a more precise classification of breast cancer with similar molecular aberrations, response treatments and outcomes, which could be attractive for therapy selection. However, currently no data are available to change our treatment recommendations according to the ‘intrinsic’ subtypes.

The **EndoPredict (EP)** score is based on the quantification of mRNA levels of 11 genes by qRT-PCR issued from FFPE samples. Its high inter-laboratory reproducibility (Pearson’s $r=0.994$) attests of its analytical validity [26]. As regards of its clinical validity, continuous EP-score was validated as an independent predictor of distant relapse in ER-positive, HER2-negative breast cancer treated with endocrine therapy ($p=0.010$). Its combination with two clinicopathologic risk factors (tumor size and nodal status) outperformed others prognosis tools like AOI or Ki67 (c-score 0.732 to 0.788). This combined marker, called EPclin, identifies risk groups with obvious differences in the 10-year distant relapse rate from 4% for low to 28% for high risk [32]. *Muller et al.* [33] studied the impact of this results on daily practice. Almost 38% of the patients were proposed to change treatment between pre- and post- EPclin test: 12% changed from endocrine to chemo-endocrine therapy while 25% change from combined treatment to endocrine treatment alone.

The **Breast Cancer Index (BCI)** combines two independent biomarkers, HOXB13:IL17BR and the 5-gene molecular grade index. It reflects the risk of distant metastasis at 10 years post-diagnosis. Among ER-positive lymph node negative disease, BCI provides new independent prognosis information for both distant-recurrence free survival (DRFS) ($p=0.0002$) and BCSS ($p<0.0001$) [34,35]. In the neoadjuvant setting, *Mathieu et al.* [36] demonstrate the ability of BCI to predict chemosensitivity with a NPV of 98.4% to achieve pCR and 86% for breast conservation surgery, for the low risk group. So far, this biomarker didn’t show added value to others gene expression assays which limited its clinical utility [37].

The **Genomic Grade Index (GGI)**, a 97 genes micro-array, created by *Sotiriou et al.* [38], reclassifies histological grade 2 (HG) patients into two groups: HG1-like or HG2-like. This approach improved the accuracy and prognostic value of HG in ER-positive invasive breast carcinoma, on a heterogeneous cohort [38–40]. High GGI tumors had a significantly higher

pCR rate after neoadjuvant chemotherapy for both ER positive [39] and negative [40] but very limited information validating the robustness of GGI is available.

Proteomic assays—The **Mammostrat®** test is an immunohistochemical (IHC) five-protein assay. Increased Mammostrat scores correlates with lower DRFS ($p=0.005$) and OS ($p=0.0023$) for ER-positive early breast cancer despite adjuvant treatment [41]. The impact of Mammostrat on breast cancer outcomes also has been shown in lymph node-positive and ER-negative disease [41,42]. The recurrence-free-survival (RFS) was improved by 21% (from 64% to 85%) for Mammostrat® high risk patients with the addition of chemotherapy to endocrine treatment [43].

The **immunohistochemical (IHC) 4** prognostic score is based on four widely measured IHC markers (ER, progesterone receptor (PgR), HER2, and Ki-67) using FFPE tumor samples. It was created and validated as a prognosis factor using the ATAC trial cohort of ER-positive early breast cancer. This inexpensive biomarker, for which three of four measures are routinely performed, could be as informative as OncotypeDx®. However, these results can only be obtained by standardized procedures because of the lack of reproducibility of IHC [44]. On this point, the International Ki67 in Breast Cancer Working Group recently proposed guidelines to reduce interlaboratory variability and improve interstudy comparability of **Ki67**, mostly using IHC with monoclonal antibody MIB1. Strengthening the analytical validity of Ki67 may enable using it for prognosis, prediction of responsiveness/resistance to endocrine therapy or chemotherapy and monitoring neoadjuvant treatment [45].

Genomic and/or proteomic approach to predict specific drugs response—

Some biomarkers could be more relevant in predicting response to specific drugs. The predictive role of **TP53**, regarding preclinical studies, remains a matter of debate concerning sensitivity to taxanes. To answer the question, *Bonnefoi et al.* [46] led a randomized phase III trial on non-metastatic chemo-naïve breast cancer. TP53 status, using yeast assay was not predictive of preferential sensitivity to taxanes. Such results were also supported by a retrospective analyze of the BIG 02-98 III trial [47].

Likewise, retrospective studies suggested an impact of the **topoisomerase 2 α** amplification/overexpression (TOP2A) on responsiveness to anthracycline-based regimens [48]. Moreover, the BCIRG-006 trial highlighted that HER2-positive breast cancers without TOP2A amplification had more benefits from trastuzumab than the all cohort, in contrast, tumors coamplified for both TOP2A and HER2 showed identical benefit in the anthracycline non trastuzumab arm and the trastuzumab arms [49]. However, standardization of measurement is mandatory because, so far, different methodological approaches (qRT-PCR, DNA microarrays, IHC or mostly fluorescence in situ hybridization (FISH)) have been used with inconsistent results and poor agreement [50]. To avoid reproducibility problem, *Desmedt et al.* [51] proposed an anthracycline-based score (A-Score) combining three signatures: *TOP2A* gene, tumor invasion and immune signatures. The A-Score was significantly associated with pCR in the anthracycline-based arm and was characterized by a high NPV of 98% either HER2-status. This score could become, if further validated, a useful clinical tool to identify patients who could avoid high risk toxicity anthracycline therapy.

The validation of new biomarkers, from in-vitro cell lines identification through prospective randomized trials, is mandatory before clinical use. The best example of such process is the **uPA/PAI-1** marker for whom the final result of the first prospective biomarker-based therapy trial ‘Chemo-N0’ just published. These 10-year results validate the benefit from adjuvant chemotherapy in the high-uPA/PAI-1 group. Thus, the American Society of

Clinical Oncology (ASCO) recognized uPA/PAI-1 as risk-group-classification markers for routine clinical decision-making in node-negative breast cancer [52].

The use of germline markers for therapy selection

Another approach in dealing with biomarkers is to study molecular specificity of the patient rather than of the tumor. Thus, Cytochrome P450 2D6 (CYP2D6) was evaluated for its implication in metabolizing tamoxifen into a clinically active metabolite. Currently results of various studies looking at this question are discordant. The largest retrospective analysis of the the BIG1-98 trial samples, didn't demonstrate an interaction between CYP2D6 phenotypes and BCSS in a tamoxifen-treated population [53]. Prospective studies are ongoing to clarify impact of CYP2D6 metabolizer on tamoxifen treatment (ECOG3108 [54] in metastatic setting). So far, this test should not be used to select adjuvant endocrine therapy.

The predictive role of BRCA1 and BRCA 2 mutations to therapy benefit have been controversial. Retrospective results suggested an enhanced response to platinum salts and reduced to taxanes in the neoadjuvant setting. [55] However, *Arun et al.* [56] demonstrated high response rates to anthracycline-taxane-based regimens in BCRA mutation carriers undergoing neoadjuvant chemotherapy. Lately, BRCA mutation status have been used as a selection biomarker for clinical trials with PARP inhibitors and platinum salts in patients with early and metastatic breast cancer [57].

Molecular testing for metastatic breast cancer

In this second part, we will review how we could monitor metastatic breast cancer evolution in order to provide an accurate and personalized treatment. We will discuss tumor tissue markers, then "liquid biopsies".

Tumor tissue markers

Over the last few years biomarkers discordance between primary tumor and disease recurrence has been a topic in the field of breast cancers. The largest retrospective study led by *Linstrom et al.* [58] revealed a discordance in ER status of 32.4% ($p < 0.001$). This discordance, confirmed in other studies, varies from 13.4% [59] to 40% [60] for ER, and correlates with worse overall survival (OS) ($p = 0.002$) [59,61]. As per HER2 status, *Niikura et al.* [62] retrospectively highlighted a 24% rate of change (ranged from 0% to 64% depends on the study), also associated with a shorter OS ($p = 0.003$) [61,62]. ER and HER2 changes were confirmed in recent prospective ConvertHER [63], DESTINY [64] and BRIT studies [65]. New markers as PTEN levels or *PI3KCA* mutational status have also shown to be discordant (26% and 18% respectively) between primary tumors and metastasis [66].

As new targeted therapies are brought into clinical trials, using primary tumor signatures for patient selection in metastatic setting might not be relevant. All these data highly suggest biological changes due to treatment exposure or natural evolution of neoplasm. New molecular signature seems mandatory to provide an accurate and relevant targeted treatment at relapse.

Pusztai et al. [67] recently presented results of the BEAT-IT study. Molecular analysis of metastatic breast cancer biopsies was successfully performed in approximately 75% for IHC (PTEN, androgen receptor, MET), FISH (*EML4-ALK*, *MET*) and mutation analysis (CMS46), without adverse events. Data were used to select clinical trials of targeted therapies, the study continues patient accrual and data on outcomes should follow. Similarly, *Andre et al.* [68] led the prospective SAFIR-001 trial. Whole-genome arrays (e.g. array

Comparative Genomic Hybridization and DNA sequencing) detected targetable genomic alteration in 70% of DNA breast cancer metastatic biopsies. The most frequent genomic alterations were *PI3KCA* mutations, *CCND1*, *FGF4* and *FGFR1* amplifications. Updated results regarding the percentage of patients who benefit from selected targeted therapy according to the molecular screening are expected. Genomic analyzes to determine a molecular target at relapse seems feasible and could notably modify our treatment options in the future.

Molecular testing utilizing blood samples

Repeat **tumor biopsy** is one of the solutions proposed by scientists. But even repeats, single snap-shots of the tumor could be insufficient to obtain an accurate genomic landscape of the breast cancer due to high intratumoral heterogeneity [69]. Moreover, tumor seeding risk [70] and adverse events of invasive techniques mostly for patients who undergone anti-angiogenic treatment could contraindicate traditional biopsy [71]. Finding more accessible biomarkers would be helpful to monitor metastatic disease and anticipated treatment response.

Circulating tumor cells—During the last decades, scientists have developed many **circulating tumor cells** (CTCs) platforms. Various technologies are employed: 1) using specific antibodies (e.g. EpCAM (epithelial cell adhesion molecule) alone or combination) in immunomagnetic (e.g. CellSearch®) or microfluidics assay; 2) using size-based filtration; 3) using electrical properties [72]. Currently, only CellSearch® is FDA approved for prognosis in metastatic breast cancer based on the prospective study of *Cristofallini et al.* [73]. Detection of ≥ 5 CTC significantly predicts worse progression free survival (PFS) and OS [74]. These results were strengthened by a recent meta-analysis, led by *Zhang et al.* [75], where CTCs detection was predictive of poor outcome irrespective of the time point of detection and the stage of breast cancer (early stage or metastatic one).

Therefore, more than a snapshot evaluation, CTCs could provide a dynamic evaluation of prognostic gradually the treatment regimens. In fact, among patients with ≥ 5 CTCs at baseline, half will have < 5 CTCs after chemotherapy courses, correlated with both increased PFS and OS ($p < 0.0001$) [73–75], thereby indicating potential chemosensitivity. Moreover, changing levels of CTCs has been correlated with radiologic response, evaluated by RECIST ($p < 0.001$) [76]. CTCs appeared to be an earlier and accurate biomarker for anticipating chemotherapy outcomes. For metastatic population treated with endocrine therapy, *Giuliano et al.* [77] couldn't show a real impact of endocrine therapy alone on CTC count which remained a strong prognostic factor at baseline. This enhances the question of more aggressive therapies for high CTC counts patients. For example anti-HER2 therapy highly targets CTCs with a decreased rate after treatment of 94 to 100% in metastatic disease [74,77]. However, for HER2-positive breast cancer treated by anti-HER2, the prognostic value of CTC is not longer sustainable because of the significant survival benefit from therapy [77,78].

The latest published studies on CTCs evaluated their HER2 expression. In fact, most of them reported a low concordance rate between HER2 status on primary or secondary tumor and CTCs from 23% to 50% [79,80]. This could define a new cohort, with poor PFS ($p = 0.036$) [81], potentially eligible for anti-HER2 treatment. Thus, a phase II study has been conducted on a small cohort of HER2-negative metastatic disease and HER2-positive CTCs, who underwent lapatinib. This clinical trial was negative for objective response rate but even so show how we could integrate CTCs analyze in future trial design [82].

The major issue regarding these “liquid biopsies” remains their analytical validity. In fact, Cellsearch®, the only FDA approve tool had low sensitivity and high false negative rate.

CTCs are currently detected in 44% to 65% of the metastatic population [74,83,84]. *Siewwert et al.* [85] revealed that normal-like breast cancer cells were undetectable by this tool because of low or no EpCAM expression. Since then, the proposed solution was to combine anti-EpCAM with other anti-epithelial antibodies - like anti-CD46 [86] or anticytokeratine [87]- or with size-based filtration. However, these solutions could be insufficient, mostly because normal-like subtype not only loose epithelial markers but also express both vimentin and TWIST1, markers of epithelial–mesenchymal transition (EMT) [85]. This discovery could potentially explain why patients considered as cured by adjuvant treatment could relapse. Furthermore, by using EpCAM+/Cytokeratine+/CD45- as definition of CTCs, 66% of patients - regardless to their metastatic status – were positive for CTCs. However, by adding more markers (e.g. ER α , HER2, ALDH1) especially EMT ones (e.g. fibronectine and vimentin), to the detection process, 34% of negative results became positive for CTCs [84]. This result strengthens the limitation of the approved standard CTC isolation test. An accurate method of detection is needed especially because CTCs gaining mesenchymal markers are associated with poorest PFS than those who don't (6.6 vs 15.3 months, $p=0.0000$), in metastatic breast cancer patients [88]. As a matter of fact, the high incidence of EMT-CTCs in metastatic versus early stage breast cancer supports the notion of EMT-CTC implication in metastatic process [84,89].

Circulating free tumor DNA—More recently, another type of “liquid biopsy” has been developed to evaluate cancer genetics: circulating free tumor DNA (cfDNA). A recent prospective study, led by *Dawson et al.* [90], on 30 metastatic breast cancers with genetic alterations (*PI3KCA*, *TP53* and structural variation) detected cfDNA in 97%. Presence of circulating DNA fragment carrying tumor sequence alterations, like mutations, promoter-methylation, could impact outcome, as summarized in Table 2.

Moreover, cfDNA appears in several studies like a prognosis marker of survival. *Dawson et al.* [90] demonstrated that an increased rate of cfDNA reduced OS ($p=0.001$). In fact, in this population, 89% of relapses were associated with an increased cfDNA level by a factor of 505 from the nadir. Furthermore, for 53% of recurrence, levels of cfDNA increased, on average 5 months before the establishment of progressive disease by imaging. The authors conclude that cfDNA often provides the earliest measure of tumor response so far. *Sorensen et al.* [91] used cfDNA to monitor treatment on 28 metastatic breast cancer treated with trastuzumab and chemotherapy. A decreased rate of cfDNA after trastuzumab treatment was observed in 40% and associated with an improved response rate ($p=0.02$) and OS ($p=0.05$). *Murtaza et al.* [92] tracked genomic evolution of metastatic disease in response to treatment by analyzing cfDNA, in few cases. For example, an activated mutation in *PIK3CA* following paclitaxel and a mutation in *MED1* following tamoxifen and trastuzumab were reported. Monitor genetic markers of treatment resistance might lead to prevent progression by changing treatment before imaging detection of relapse or increased cfDNA levels.

Lack of standardization in cfDNA detection is the main issue to access an accurate analytical validity. In fact, DNA can be extracted from plasma or serum and genetic alterations can be analyzed by several technical tools with limitations for each of them: a prior tumor biopsy is needed to select the mutation to monitor for some (e.g. digital PCR [90], BEAMing [93]); high quality DNA is needed for large analyze of genetic landscape for others expansive ones (New generation of Sequencing (NGS) [90]).

Up to now, high detection rates are not reproducible in early stage cancer probably because of insufficient DNA quantity of low tumor burden [94,95]. Moreover, discordant results concerning the specificity of cfDNA detection at baseline, is raising an issue because of high false positives in benign lesions in some cohorts [96,97].

Disseminated tumor cells in bone marrow

Disseminated tumor cells in bone marrow (DTC-BM) were found to be prognostic in metastatic disease at the beginning of the 2000's. BM aspiration has a limited ability for repeated measures because it is an invasive and painful procedure. As a consequence, CTCs detection currently surpasses this tool thanks to more convenient patient procedure and significant congruence between DTC-BM and CTC [98]. However one needs to remember that DTC may have a different biological significance compared to CTCs and further studies are granted.

Conclusion

Up to date, evidence suggests that some women with ER-positive disease might be cured by endocrine therapy alone whereas others require chemotherapy. The main issue with the majority of the available tests that claim to be predictive is the clear lack of clinical validity. Results of ongoing prospective randomized clinical trials will strengthen this weakness.

Using primary tumor signatures for patient selection in metastatic setting is not standard practice, but a good screening tool for clinical trials of targeted therapies as they can have a initial validation on the go. Circulating biomarkers will allow better monitoring of metastatic disease.

Acknowledgments

This work was supported in part by a grant from the Eugène Marquis Cancer Center, Rennes, France (to F. Le Du), National Cancer Institute 1K23CA121994 (A.M. Gonzalez-Angulo), ASCO Career Development Award (A.M. Gonzalez-Angulo), Komen for the Cure Catalytic Award KG090341 (A.M. Gonzalez-Angulo), Komen for the Cure SAC 100004, American Cancer Society Research Scholar Grant 121329-RSG-11-187-01-TBG (A.M. Gonzalez-Angulo), Commonwealth Foundation for Cancer Research (A.M. Gonzalez-Angulo), and National Cancer Institute through The University of Texas MD Anderson's Cancer Center Support Grant (P30 CA016672).

References

Recently published papers of particular interest have been highlighted:

* Of importance

** Of major importance

1. Čufer T. Which tools can I use in daily clinical practice to improve tailoring of treatment for breast cancer? The 2007 St Gallen guidelines and/or Adjuvant! Online. *Ann Oncol.* 2008; 19:vii41–vii45. [PubMed: 18790977]
2. Guiu S, Michiels S, André F, et al. Molecular subclasses of breast cancer: how do we define them? The IMPAKT 2012 Working Group Statement. *Ann Oncol.* 2012; 23:2997–3006. [PubMed: 23166150]
3. Ramsey SD, Barlow WE, Gonzalez-Angulo AM, et al. Integrating comparative effectiveness design elements and endpoints into a phase III, randomized clinical trial (SWOG S1007) evaluating oncotypeDX-guided management for women with breast cancer involving lymph nodes. *Contemp Clin Trials.* 2013; 34:1–9. [PubMed: 23000081]
4. Paik S, Shak S, Tang G, et al. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. *N Engl J Med.* 2004; 351:2817–2826. [PubMed: 15591335]
5. Harris L, Fritsche H, Mennel R, et al. American Society of Clinical Oncology 2007 Update of Recommendations for the Use of Tumor Markers in Breast Cancer. *J Clin Oncol.* 2007; 25:5287–5312. [PubMed: 17954709]
6. National Comprehensive Cancer Network Practice Guidelines in Oncology. Breast Cancer. (version v3.2012). <http://www.nccn.org>

7. Aebi S, Davidson T, Gruber G, Castiglione M. Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. *Ann Oncol.* 2010; 21:v9–v14. [PubMed: 20555111]
8. Habel LA, Shak S, Jacobs MK, et al. A population-based study of tumor gene expression and risk of breast cancer death among lymph node-negative patients. *Breast Cancer Res.* 2006; 8:R25. [PubMed: 16737553]
9. Paik, S. Expression of the 21 genes in the Recurrence Score assay and tamoxifen clinical benefit in the NSABP study B-14 of node negative, estrogen receptor positive breast cancer [abstract 510]. Presented at the 2005 ASCO Annual Meeting;
10. Paik S, Tang G, Shak S, et al. Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer. *J Clin Oncol.* 2006; 24:3726–3734. [PubMed: 16720680]
11. Dowsett M, Cuzick J, Wale C, et al. Prediction of Risk of Distant Recurrence Using the 21-Gene Recurrence Score in Node-Negative and Node-Positive Postmenopausal Patients With Breast Cancer Treated With Anastrozole or Tamoxifen: A TransATAC Study. *J Clin Oncol.* 2010; 28:1829–1834. [PubMed: 20212256]
12. Albain KS, Barlow WE, Shak S, et al. Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trial. *Lancet Oncol.* 2010; 11:55–65. [PubMed: 20005174]
13. Bryant, J. Oncotype Dx correlates more closely with prognosis than Adjuvant Online. Presented at the 9th International Conference on Primary Therapy of Early Breast Cancer; 2005; St Gallen, Switzerland.
14. Kelly CM, Bernard PS, Krishnamurthy S, et al. Agreement in risk prediction between the 21-gene recurrence score assay (Oncotype DX®) and the PAM50 breast cancer intrinsic Classifier™ in early-stage estrogen receptor-positive breast cancer. *Oncologist.* 2012; 17:492–498. [PubMed: 22418568]
15. Albanell J, González A, Ruiz-Borrego M, et al. Prospective transGEICAM study of the impact of the 21-gene Recurrence Score assay and traditional clinicopathological factors on adjuvant clinical decision making in women with estrogen receptor-positive (ER+) node-negative breast cancer. *Ann Oncol.* 2012; 23:625–631. [PubMed: 21652577]
16. Eiermann W, Rezai M, Kümmel S, et al. The 21-gene recurrence score assay impacts adjuvant therapy recommendations for ER-positive, node-negative and node-positive early breast cancer resulting in a risk-adapted change in chemotherapy use. *Ann Oncol.* 2013; 24:618–624. [PubMed: 23136233]
17. Sparano JA, Paik S. Development of the 21-Gene Assay and Its Application in Clinical Practice and Clinical Trials. *J Clin Oncol.* 2008; 26:721–728. [PubMed: 18258979]
18. ClinicalTrials.gov. Hormone Therapy With or Without Combination Chemotherapy in Treating Women Who Have Undergone Surgery for Node-Negative Breast Cancer (The TAILORx Trial). Clin. NCT00310180.
19. Van de Vijver MJ, He YD, van't Veer LJ, et al. A gene-expression signature as a predictor of survival in breast cancer. *N Engl J Med.* 2002; 347:1999–2009. [PubMed: 12490681]
20. Van't Veer LJ, Dai H, van de Vijver MJ, et al. Gene expression profiling predicts clinical outcome of breast cancer. *Nature.* 2002; 415:530–536. [PubMed: 11823860]
21. Buyse M, Loi S, van't Veer L, et al. Validation and clinical utility of a 70-gene prognostic signature for women with node-negative breast cancer. *J Natl Cancer Inst.* 2006; 98:1183–1192. [PubMed: 16954471]
22. Bueno-de-Mesquita JM, van Harten WH, Retel VP, et al. Use of 70-gene signature to predict prognosis of patients with node-negative breast cancer: a prospective community-based feasibility study (RASTER). *Lancet Oncol.* 2007; 8:1079–1087. [PubMed: 18042430]
23. Bueno-de-Mesquita JM, Sonke GS, van de Vijver MJ, Linn SC. Additional value and potential use of the 70-gene prognosis signature in node-negative breast cancer in daily clinical practice. *Ann Oncol.* 2011; 22:2021–2030. [PubMed: 19955335]

24. Knauer M, Mook S, Rutgers EJT, et al. The predictive value of the 70-gene signature for adjuvant chemotherapy in early breast cancer. *Breast Cancer Res Treat.* 2010; 120:655–661. [PubMed: 20204499]
25. Straver ME, Glas AM, Hannemann J, et al. The 70-gene signature as a response predictor for neoadjuvant chemotherapy in breast cancer. *Breast Cancer Res Treat.* 2010; 119:551–558. [PubMed: 19214742]
26. Rutgers E, Piccart-Gebhart MJ, Bogaerts J, et al. The EORTC 10041/BIG 03-04 MINDACT trial is feasible: results of the pilot phase. *Eur J Cancer Oxf Engl 1990.* 2011; 47:2742–2749.
27. ClinicalTrials.gov. Genetic Testing or Clinical Assessment in Determining the Need for Chemotherapy in Women With Breast Cancer That Involves No More Than 3 Lymph Nodes. Clin. NCT00433589.
28. Sørli T, Perou CM, Tibshirani R, et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. *Proc Natl Acad Sci U S A.* 2001; 98:10869–10874. [PubMed: 11553815]
29. Parker JS, Mullins M, Cheang MCU, et al. Supervised risk predictor of breast cancer based on intrinsic subtypes. *J Clin Oncol.* 2009; 27:1160–1167. [PubMed: 19204204]
30. Esserman LJ, Berry DA, Cheang MCU, et al. Chemotherapy response and recurrence-free survival in neoadjuvant breast cancer depends on biomarker profiles: results from the I-SPY 1 TRIAL (CALGB 150007/150012; ACRIN 6657). *Breast Cancer Res Treat.* 2012; 132:1049–1062. [PubMed: 22198468]
31. Denkert C, Kronenwett R, Schlake W, et al. Decentral gene expression analysis for ER+/Her2- breast cancer: results of a proficiency testing program for the EndoPredict assay. *Virchows Arch Int J Pathol.* 2012; 460:251–259.
32. Filipits M, Rudas M, Jakesz R, et al. A new molecular predictor of distant recurrence in ER-positive, HER2-negative breast cancer adds independent information to conventional clinical risk factors. *Clin Cancer Res.* 2011; 17:6012–6020. [PubMed: 21807638]
33. Müller BM, Keil E, Lehmann A, et al. The EndoPredict Gene-Expression Assay in Clinical Practice - Performance and Impact on Clinical Decisions. *PloS One.* 2013; 8:e68252. [PubMed: 23826382]
34. Jankowitz RC, Cooper K, Erlander MG, et al. Prognostic utility of the breast cancer index and comparison to Adjuvant! Online in a clinical case series of early breast cancer. *Breast Cancer Res.* 2011; 13:R98. [PubMed: 21999244]
35. Jerevall P-L, Ma X-J, Li H, et al. Prognostic utility of HOXB13:IL17BR and molecular grade index in early-stage breast cancer patients from the Stockholm trial. *Br J Cancer.* 2011; 104:1762–1769. [PubMed: 21559019]
36. Mathieu MC, Mazouni C, Kesty NC, et al. Breast Cancer Index predicts pathological complete response and eligibility for breast conserving surgery in breast cancer patients treated with neoadjuvant chemotherapy. *Ann Oncol.* 2012; 23:2046–2052. [PubMed: 22112967]
37. Azim HA Jr, Michiels S, Zagouri F, et al. Utility of prognostic genomic tests in breast cancer practice: The IMPAKT 2012 Working Group Consensus Statement. *Ann Oncol.* 2013; 24:647–654. [PubMed: 23337633]
38. Sotiriou C, Wirapati P, Loi S, et al. Gene expression profiling in breast cancer: understanding the molecular basis of histologic grade to improve prognosis. *J Natl Cancer Inst.* 2006; 98:262–272. [PubMed: 16478745]
39. Naoi Y, Kishi K, Tanei T, et al. High genomic grade index associated with poor prognosis for lymph node-negative and estrogen receptor-positive breast cancers and with good response to chemotherapy. *Cancer.* 2011; 117:472–479. [PubMed: 20878674]
40. Liedtke C, Hatzis C, Symmans WF, et al. Genomic grade index is associated with response to chemotherapy in patients with breast cancer. *J Clin Oncol.* 2009; 27:3185–3191. [PubMed: 19364972]
41. Bartlett JM, Thomas J, Ross DT, et al. Mammostrat® as a tool to stratify breast cancer patients at risk of recurrence during endocrine therapy. *Breast Cancer Res.* 2010; 12:R47. [PubMed: 20615243]

42. Bartlett JMS, Bloom KJ, Piper T, et al. Mammostrat as an immunohistochemical multigene assay for prediction of early relapse risk in the tamoxifen versus exemestane adjuvant multicenter trial pathology study. *J Clin Oncol.* 2012; 30:4477–4484. [PubMed: 23045591]
43. Ross DT, Kim C-y, Tang G, et al. Chemosensitivity and Stratification by a Five Monoclonal Antibody Immunohistochemistry Test in the NSABP B14 and B20 Trials. *Clin Cancer Res.* 2008; 14:6602–6609. [PubMed: 18927301]
44. Cuzick J, Dowsett M, Pineda S, et al. Prognostic value of a combined estrogen receptor, progesterone receptor, Ki-67, and human epidermal growth factor receptor 2 immunohistochemical score and comparison with the Genomic Health recurrence score in early breast cancer. *J Clin Oncol.* 2011; 29:4273–4278. [PubMed: 21990413]
45. Dowsett M, Nielsen TO, A'Hern R, et al. Assessment of Ki67 in Breast Cancer: Recommendations from the International Ki67 in Breast Cancer Working Group. *JNCI J Natl Cancer Inst.* 2011; 103:1656–1664.
46. Bonnefoi H, Piccart M, Bogaerts J, et al. TP53 status for prediction of sensitivity to taxane versus non-taxane neoadjuvant chemotherapy in breast cancer (EORTC 10994/BIG 1-00): a randomised phase 3 trial. *Lancet Oncol.* 2011; 12:527–539. [PubMed: 21570352]
47. Fernández-Cuesta L, Oakman C, Falagan-Lotsch P, et al. Prognostic and predictive value of TP53 mutations in node-positive breast cancer patients treated with anthracycline- or anthracycline/taxane-based adjuvant therapy: results from the BIG 02-98 phase III trial. *Breast Cancer Res.* 2012; 14:R70. [PubMed: 22551440]
48. Press MF, Sauter G, Buyse M, et al. Alteration of Topoisomerase II-Alpha Gene in Human Breast Cancer: Association With Responsiveness to Anthracycline-Based Chemotherapy. *J Clin Oncol.* 2010; 29:859–867. [PubMed: 21189395]
49. Slamon D, Eiermann W, Robert N, et al. Adjuvant Trastuzumab in HER2-Positive Breast Cancer. *N Engl J Med.* 2011; 365:1273–1283. [PubMed: 21991949]
50. Romero A, Martín M, Cheang MCU, et al. Assessment of Topoisomerase II α status in breast cancer by quantitative PCR, gene expression microarrays, immunohistochemistry, and fluorescence in situ hybridization. *Am J Pathol.* 2011; 178:1453–1460. [PubMed: 21435434]
51. Desmedt C, Di Leo A, de Azambuja E, et al. Multifactorial Approach to Predicting Resistance to Anthracyclines. *J Clin Oncol.* 2011; 29:1578–1586. [PubMed: 21422418]
52. Harbeck N, Schmitt M, Meisner C, et al. Ten-year analysis of the prospective multicentre ChemO trial validates American Society of Clinical Oncology (ASCO)-recommended biomarkers uPA and PAI-1 for therapy decision making in node-negative breast cancer patients. *Eur J Cancer Oxf Engl 1990.* 2013; 49:1825–1835.
53. Regan MM, Leyland-Jones B, Bouzyk M, et al. CYP2D6 genotype and tamoxifen response in postmenopausal women with endocrine-responsive breast cancer: the breast international group 1-98 trial. *J Natl Cancer Inst.* 2012; 104:441–451. [PubMed: 22395644]
54. ClinicalTrials.gov. Tamoxifen Citrate, Letrozole, Anastrozole, or Exemestane With or Without Chemotherapy in Treating Patients With Invasive RxPONDER Breast Cancer. Clin. NCT01272037.
55. Byrski T, Gronwald J, Huzarski T, et al. Pathologic complete response rates in young women with BRCA1-positive breast cancers after neoadjuvant chemotherapy. *J Clin Oncol.* 2010; 28:375–379. [PubMed: 20008645]
56. Arun B, Bayraktar S, Liu DD, et al. Response to neoadjuvant systemic therapy for breast cancer in BRCA mutation carriers and noncarriers: a single-institution experience. *J Clin Oncol.* 2011; 29:3739–3746. [PubMed: 21900106]
57. ClinicalTrials.gov. Carboplatin or Docetaxel in Treating Women With Metastatic Genetic Breast Cancer. Clin. NCT00321633.
58. Lindstrom LS, Karlsson E, Wilking UM, et al. Clinically Used Breast Cancer Markers Such As Estrogen Receptor, Progesterone Receptor, and Human Epidermal Growth Factor Receptor 2 Are Unstable Throughout Tumor Progression. *J Clin Oncol.* 2012; 30:2601–2608. [PubMed: 22711854]

59. Dieci MV, Barbieri E, Piacentini F, et al. Discordance in receptor status between primary and recurrent breast cancer has a prognostic impact: a single-Institution analysis. *Ann Oncol.* 2012; 24:101–108. [PubMed: 23002281]
60. Simmons C, Miller N, Geddie W, et al. Does confirmatory tumor biopsy alter the management of breast cancer patients with distant metastases? *Ann Oncol.* 2009; 20:1499–1504. [PubMed: 19299408]
61. Liedtke C, Broglio K, Moulder S, et al. Prognostic impact of discordance between triple-receptor measurements in primary and recurrent breast cancer. *Ann Oncol.* 2009; 20:1953–1958. [PubMed: 19596702]
62. Niikura N, Liu J, Hayashi N, et al. Loss of Human Epidermal Growth Factor Receptor 2 (HER2) Expression in Metastatic Sites of HER2-Overexpressing Primary Breast Tumors. *J Clin Oncol.* 2011; 30:593–599. [PubMed: 22124109]
63. de Dueñas, Martinez. Prospective Evaluation of the Conversion Rate of HER2, ER and PR between Primary Tumors and Corresponding Metastases. CONVERTHER/GEICAM 2009-03 Study. [Poster P2-12-17] Presented at SABCs 2011. *Cancer Res.* 2011; 71(24 Suppl)
64. Amir E, Miller N, Geddie W, et al. Prospective Study Evaluating the Impact of Tissue Confirmation of Metastatic Disease in Patients With Breast Cancer. *J Clin Oncol.* 2011; 30:587–592. [PubMed: 22124102]
65. Thompson AM, Jordan LB, Quinlan P, et al. Prospective comparison of switches in biomarker status between primary and recurrent breast cancer: the Breast Recurrence In Tissues Study (BRITS). *Breast Cancer Res.* 2010; 12:R92. [PubMed: 21059212]
66. Gonzalez-Angulo AM, Ferrer-Lozano J, Stemke-Hale K, et al. PI3K Pathway Mutations and PTEN Levels in Primary and Metastatic Breast Cancer. *Mol Cancer Ther.* 2011; 10:1093–1101. [PubMed: 21490305]
67. Pusztai L. Breast cancer evaluation and targeted investigational therapy (BEAT-IT): A pilot prospective tissue testing to guide clinical trial selection. *J Clin Oncol.* 2013; 31 (suppl; abstr 532); 2013.
68. Andre F. Array CGH and DNA sequencing to personalize targeted treatment of metastatic breast cancer (MBC) patients (pts): A prospective multicentric trial (SAFIR01). *J Clin Oncol.* 2013; 31 (suppl; abstr 511); 2013.
69. Gerlinger M, Rowan AJ, Horswell S, et al. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. *N Engl J Med.* 2012; 366:883–892. [PubMed: 22397650]
70. Robertson EG, Baxter G. Tumour seeding following percutaneous needle biopsy: the real story! *Clin Radiol.* 2011; 66:1007–1014. [PubMed: 21784421]
71. Hompes D, Ruers T. Review: incidence and clinical significance of Bevacizumab-related non-surgical and surgical serious adverse events in metastatic colorectal cancer. *Eur J Surg Oncol.* 2011; 37:737–746. [PubMed: 21764243]
72. Kling J. Beyond counting tumor cells. *Nat Biotechnol.* 2012; 30:578–580. [PubMed: 22781672]
73. Cristofanilli M, Budd GT, Ellis MJ, et al. Circulating tumor cells, disease progression, and survival in metastatic breast cancer. *N Engl J Med.* 2004; 351:781–791. [PubMed: 15317891]
74. Pierga J-Y, Hajage D, Bachelot T, et al. High independent prognostic and predictive value of circulating tumor cells compared with serum tumor markers in a large prospective trial in first-line chemotherapy for metastatic breast cancer patients. *Ann Oncol.* 2012; 23:618–624. [PubMed: 21642515]
75. Zhang L, Riethdorf S, Wu G, et al. Meta-analysis of the prognostic value of circulating tumor cells in breast cancer. *Clin Cancer Res.* 2012; 18:5701–5710. [PubMed: 22908097]
76. Hartkopf AD, Wagner P, Wallwiener D, Fehm T, Rothmund R. Changing levels of circulating tumor cells in monitoring chemotherapy response in patients with metastatic breast cancer. *Anticancer Res.* 2011; 31:979–984. [PubMed: 21498725]
77. Giuliano M, Giordano A, Jackson S, et al. Circulating tumor cells as prognostic and predictive markers in metastatic breast cancer patients receiving first-line systemic treatment. *Breast Cancer Res.* 2011; 13:R67. [PubMed: 21699723]

78. Giordano A, Giuliano M, De Laurentiis M, et al. Circulating tumor cells in immunohistochemical subtypes of metastatic breast cancer: lack of prediction in HER2-positive disease treated with targeted therapy. *Ann Oncol*. 2012; 23:1144–1150. [PubMed: 21965473]
79. Fehm T, Müller V, Aktas B, et al. HER2 status of circulating tumor cells in patients with metastatic breast cancer: a prospective, multicenter trial. *Breast Cancer Res Treat*. 2010; 124:403–412. [PubMed: 20859679]
80. Somlo G, Lau SK, Frankel P, et al. Multiple biomarker expression on circulating tumor cells in comparison to tumor tissues from primary and metastatic sites in patients with locally advanced/inflammatory, and stage IV breast cancer, using a novel detection technology. *Breast Cancer Res Treat*. 2011; 128:155–163. [PubMed: 21499685]
81. Munzone E, Nolè F, Goldhirsch A, et al. Changes of HER2 status in circulating tumor cells compared with the primary tumor during treatment for advanced breast cancer. *Clin Breast Cancer*. 2010; 10:392–397. [PubMed: 20920984]
82. Pestrin M, Bessi S, Puglisi F, et al. Final results of a multicenter phase II clinical trial evaluating the activity of single-agent lapatinib in patients with HER2-negative metastatic breast cancer and HER2-positive circulating tumor cells. A proof-of-concept study. *Breast Cancer Res Treat*. 2012; 134:283–289. [PubMed: 22476856]
83. Mego M, De Giorgi U, Dawood S, et al. Characterization of metastatic breast cancer patients with nondetectable circulating tumor cells. *Int J Cancer J Int Cancer*. 2011; 129:417–423.
84. Raimondi C, Gradilone A, Naso G, et al. Epithelial-mesenchymal transition and stemness features in circulating tumor cells from breast cancer patients. *Breast Cancer Res Treat*. 2011; 130:449–455. [PubMed: 21298334]
85. Sieuwerts AM, Kraan J, Bolt J, et al. Anti-epithelial cell adhesion molecule antibodies and the detection of circulating normal-like breast tumor cells. *J Natl Cancer Inst*. 2009; 101:61–66. [PubMed: 19116383]
86. Mostert B, Kraan J, Bolt-de Vries J, et al. Detection of circulating tumor cells in breast cancer may improve through enrichment with anti-CD146. *Breast Cancer Res Treat*. 2011; 127:33–41. [PubMed: 20379845]
87. Weissenstein U, Schumann A, Reif M, Link S, Toffol-Schmidt UD, Heusser P. Detection of circulating tumor cells in blood of metastatic breast cancer patients using a combination of cytokeratin and EpCAM antibodies. *BMC Cancer*. 2012; 12:206. [PubMed: 22646670]
88. Gradilone A, Raimondi C, Nicolazzo C, et al. Circulating tumour cells lacking cytokeratin in breast cancer: the importance of being mesenchymal. *J Cell Mol Med*. 2011; 15:1066–1070. [PubMed: 21352474]
89. Kallergi G, Papadaki MA, Politaki E, Mavroudis D, Georgoulas V, Agelaki S. Epithelial to mesenchymal transition markers expressed in circulating tumour cells of early and metastatic breast cancer patients. *Breast Cancer Res*. 2011; 13:R59. [PubMed: 21663619]
90. Dawson S-J, Tsui DWY, Murtaza M, et al. Analysis of circulating tumor DNA to monitor metastatic breast cancer. *N Engl J Med*. 2013; 368:1199–1209. [PubMed: 23484797]
91. Sorensen BS, Mortensen LS, Andersen J, Nexø E. Circulating HER2 DNA after trastuzumab treatment predicts survival and response in breast cancer. *Anticancer Res*. 2010; 30:2463–2468. [PubMed: 20651409]
92. Murtaza M, Dawson S-J, Tsui DWY, et al. Non-invasive analysis of acquired resistance to cancer therapy by sequencing of plasma DNA. *Nature*. 2013; 497:108–112. [PubMed: 23563269]
93. Higgins MJ, Jelovac D, Barnathan E, et al. Detection of tumor PIK3CA status in metastatic breast cancer using peripheral blood. *Clin Cancer Res*. 2012; 18:3462–3469. [PubMed: 22421194]
94. Board RE, Wardley AM, Dixon JM, et al. Detection of PIK3CA mutations in circulating free DNA in patients with breast cancer. *Breast Cancer Res Treat*. 2010; 120:461–467. [PubMed: 20107891]
95. Bechmann T, Andersen RF, Pallisgaard N, et al. Plasma HER2 amplification in cell-free DNA during neoadjuvant chemotherapy in breast cancer. *J Cancer Res Clin Oncol*. 2013; 139:995–1003. [PubMed: 23479212]
96. Roth C, Pantel K, Müller V, et al. Apoptosis-related deregulation of proteolytic activities and high serum levels of circulating nucleosomes and DNA in blood correlate with breast cancer progression. *BMC Cancer*. 2011; 11:4. [PubMed: 21211028]

97. Hashad D, Sorour A, Ghazal A, Talaat I. Free circulating tumor DNA as a diagnostic marker for breast cancer. *J Clin Lab Anal.* 2012; 26:467–472. [PubMed: 23143630]
98. Schindlbeck C, Andergassen U, Hofmann S, et al. Comparison of circulating tumor cells (CTC) in peripheral blood and disseminated tumor cells in the bone marrow (DTC-BM) of breast cancer patients. *J Cancer Res Clin Oncol.* 2013; 139:1055–1062. [PubMed: 23525580]
99. Müller HM, Widschwendter A, Fiegl H, et al. DNA methylation in serum of breast cancer patients: an independent prognostic marker. *Cancer Res.* 2003; 63:7641–7645. [PubMed: 14633683]
100. Yamamoto N, Nakayama T, Kajita M, et al. Detection of aberrant promoter methylation of GSTP1, RASSF1A, and RAR β 2 in serum DNA of patients with breast cancer by a newly established one-step methylation-specific PCR assay. *Breast Cancer Res Treat.* 2012; 132:165–173. [PubMed: 21594664]

Table 1

Summary of gene expression assays in early stage breast cancer [2,37]

Assay	Tissue sample	Method	Number of Genes/Proteins	Analytical validity	Clinical validity	Ongoing clinical prospective studies	Patients
OncotypeDX®	FFPE	qRT-PCR	21	YES[8]	YES[4,8,11]	TAILORx trial[18]	N±ER+
Mammaprint®	Fresh frozen/FFPE	DNA microarray	70	YES[21]	YES[19,20,24,25]	MINDACT trial[27]	N±ER±
PAM50	FFPE	qRT-PCR	50	NO	YES[29,30]	NO	N±ER+
EndoPredict	FFPE	qRT-PCR	11	YES[31]	YES[32,33]	NO	N±ER+
Breast Cancer Index	FFPE	qRT-PCR	7	NO	YES[34–36]	NO	N–ER+
GGI	Fresh frozen	DNA microarray	97	NO	NO	NO	N±ER±

Abbreviations: FFPE using formalin-fixed paraffin-embedded, qRT-PCR quantitative reverse transcriptase-PCR

Table 2

Clinical impact of cfDNA detection in metastatic setting

Study (year)	Patients (n)	Source	Technique	Genetic alterations monitored	Clinical impact
Müller et al. (2003)[99]	10	Serum	MethylLight	RASSF1A and/or APC methylation	na
Board et al. (2010)[94]	72	Plasma Serum	ARMS-Scorpion PCR	PI3KCA	na
Higgins et al.(2012)[93]	85	Plasma	BEAMing	PI3KCA	na
Sorensen et al(2010)[91]	28	Plasma	Real-time PCR	HER2	Decreased cfDNA increased OS (p=0.05)
Yamamoto et al (2012)[100]	58	Serum	OS-MSP	RASSF1A, GSTP1 and RARβ methylation	na
Dawson et al. (2013)[90]	30	Plasma	Digital PCR, Tam-Seq	PI3KCA, TP53, structural variation	Increased cfDNA reduced OS (p<0.001)

Abbreviations: OS-MSP one-step methylation-specific polymerase chain reaction PCR Polymerase Chain Reaction